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A B S T R A C T
Bronchial Thermoplasty (BT) is an endoscopic treatment for moderate-to-severe asthma patients who are un-
controlled despite optimal medical therapy. Eﬀectiveness of BT has been demonstrated in several randomized
clinical trials. However, the asthma phenotype that beneﬁts most of this treatment is unclear, partly because the
mechanism of action is incompletely understood. BT was designed to reduce the amount of airway smooth
muscle (ASM), but additional direct and indirect eﬀects on airway pathophysiology are expected. This review
will provide an overview of the diﬀerent components of airway pathophysiology including remodeling, with the
ASM as the key player. Current concepts in the understanding of BT clinical eﬀectiveness with a focus on its
impact on airway remodeling will be reviewed.
1. Introduction
Severe asthma is deﬁned as uncontrolled asthma despite, or con-
trolled asthma requiring, the use of high dose inhaled corticosteroids
(ICS) next to a second controller and/or systemic oral corticosteroids
(OCS) (Bel et al., 2011; Chung et al., 2014). This group represents
3.6%–10% of asthma patients and is known to have a high burden of
disease with frequent asthma exacerbations and/or progressive lung
function decline resulting in excessive utilization of health care re-
sources (Barnes &Woolcock, 1998; Busse, Banks-Schlegel, &Wenzel,
2000; Hekking et al., 2015; O'Byrne, Naji, & Gauvreau, 2012).
The treatment approach of severe asthma is described in the Global
Initiative for Asthma (GINA) guideline step 4 and 5. GINA step 4 ranges
from medium to high dose ICS with a long acting beta-agonist (LABA),
and/or an extra controller such as tiotropium, leukotriene modiﬁer or
theophylline. When asthma control is not achieved within GINA step 4,
GINA step 5 advises add-on treatment including tiotropium, anti-IgE,
anti-interleukin 5 (anti-IL5) and low dose OCS (“Global Initiative for
Asthma. Global Strategy for Asthma Management and Prevention,
2016. Available from: www.ginasthma.org”). Driven by improved
phenotyping, these add-on treatments are now increasingly prescribed
to distinct asthma phenotypes (Chung et al., 2014). For example anti-
IgE can be considered in patients with a predominant allergic pheno-
type, and anti-IL5 in patients with a predominant eosinophilic pheno-
type (Trivedi, Pavord, & Castro, 2016). For patients with predominant
chronic airﬂow obstruction or patients with unsatisfactory response to,
or who are not eligible for anti-IgE or anti-IL5, Bronchial Thermoplasty
(BT) can be considered (“British Thoracic Society, Scottish
Intercollegiate Guidelines Network. British guideline on the manage-
ment of asthma, 2016. Available from: www.brit-thoracic.org.uk_
document-library_clinical-information_asthma_btssign-asthma-
guideline-2016”; “Global Initiative for Asthma. Global Strategy for
Asthma Management and Prevention, 2016. Available from: www.
ginasthma.org”; Trivedi et al., 2016).
Unfortunately, the mechanism of action of this relatively new, en-
doscopic treatment for asthma is incompletely understood. More insight
in distinct phenotypes of asthma and pathways targeted by BT is needed
to identify the asthma phenotype that beneﬁts most of BT (Anderson,
2008; Gauthier, Ray, &Wenzel, 2015; Lotvall et al., 2011; Ray,
Raundhal, Oriss, Ray, &Wenzel, 2016). Therefore, we review potential
targets for BT, particularly those related to airway remodeling, in-
cluding airway smooth muscle (ASM), extracellular matrix (ECM),
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inﬂammation, neural innervation and vascular function.
2. Airway remodeling and innervation in asthma
Asthma is characterized by airway remodeling which is deﬁned as
an alteration of the tissue structure and cells in the airways
(James &Wenzel, 2007; Jeﬀery, 2001). Features of altered airway his-
tology in asthma include a thickened epithelium, increased ECM in-
cluding reticular basement membrane (RBM) thickening, ASM hyper-
plasia and hypertrophy, inﬂammation, vascular activation and
angiogenesis and mucous gland hypertrophy (Bousquet et al., 1992;
James &Wenzel, 2007; Jeﬀery, 2001).
2.1. Airway smooth muscle (ASM) in asthma
Key feature of airway remodeling in asthma is the altered ASM. This
includes thickening of the ASM layer surrounding the airways, caused
by ASM hypertrophy and hyperplasia as described in post-mortem
specimens of patients with asthma (Bai, 1990; Carroll, Elliot,
Morton, & James, 1993; Dunnill, Massarella, & Anderson, 1969;
Hossain &Heard, 1970). More speciﬁc, James et al. found ASM hyper-
trophy in large airways in both non-fatal and fatal post-mortem asthma
cases, whereas hyperplasia of ASM cells was present in the large and
small airways in fatal asthma cases only (James et al., 2012).
Benayoun and colleagues assessed the degree of airway remodeling
in bronchial biopsies from asthma patients ranging from intermittent to
severe asthma in relation to controls and found that ﬁbroblast accu-
mulation and increase in ASM mass where associated with asthma se-
verity (Benayoun, Druilhe, Dombret, Aubier, & Pretolani, 2003). Inter-
estingly, it was shown that an increased ASM mass in pre-school
wheezers can predict the development of asthma at school age (O'Reilly
et al., 2013). In addition it has been reported that ASM in pre-schoolers
with severe recurrent wheeze with atopy is increased as compared to
pre-schoolers with severe recurrent wheeze without atopy. Never-
theless, no relation was found between inﬂammatory cell counts and
the morphometrics of the airway wall (including vascularity, mucous
gland area, RBM thickness and epithelial integrity) (Lezmi et al., 2015).
These early ﬁndings of ASM alterations in pre-schoolers with severe
recurrent wheeze with atopy, a group at high risk of developing asthma,
make it plausible that airway remodeling including ASM alterations is
an intrinsic feature of asthma and not solely a consequence of in-
ﬂammation (Lezmi et al., 2015).
ASM contraction is considered the key eﬀector of bronchoconstric-
tion. Based on the increased sensitivity and increased response to
bronchoconstrictive stimuli in asthma patients the ASM is likely to play
an important role in airway hyperresponsiveness (AHR) (Dulin et al.,
2003; Nair et al., 2017). However, the exact mechanism and role of the
ASM in AHR is not completely understood. Most in vitro studies did not
show an increase in maximal force-generating capacity of asthmatic
tissues to various bronchoconstrictive stimuli (McParland,
Macklem, & Pare, 2003). On the other hand, in vitro studies comparing
ASM contractility of ASM cells and tissues from asthmatic and non-
asthmatics, did ﬁnd that the shortening of ASM of asthmatics is greater
than that from non-asthmatics (Ma et al., 2002; McParland et al., 2003;
Stephens, Li, Jiang, Unruh, &Ma, 2003). This suggests that the changed
ASM and related increased contractility are more determined by the
shortening ability instead of the maximal generating force capacity.
The principal function of ASM cells, contractile or synthetic, is likely
to be determined by diﬀerentiation of ASM cells into diﬀerent pheno-
types as suggested by gene expression studies in patients with asthma
and controls (Yick et al., 2013, 2014). Indeed, in vitro results demon-
strated that exposure of ASM cells to a mitogenic stimulus results in a
reversible modulation in phenotype from contractile to synthetic
(Chamley-Campbell, Campbell, & Ross, 1979; Owens, 1995). Con-
tractile phenotype ASM cells are characterized by high levels of con-
tractile proteins and less biosynthetic organelles, and retain their ability
to contract. In contrast the ASM cells with a synthetic phenotype con-
tain less contractile proteins and more biosynthetic organelles which
may impair their ability to contract (Hirst, Walker, & Chilvers, 2000).
This might be related to altered gene expression proﬁles of ASM ob-
served in mild asthma patients with hyperresponsiveness (Yick et al.,
2014). These physiological and biological ﬁndings in mild asthma pa-
tients require further investigation in patients with more severe asthma.
Next to the changes in amount, contractile and gene expression
proﬁles of ASM observed in asthma described above, the ASM is con-
sidered an important source of inﬂammatory cytokines and chemokines
(Chang, Bhavsar, Michaeloudes, Khorasani, & Chung, 2012; Hirst, 2003;
Koziol-White & Panettieri, 2011). As such ASM might have a potential
role in the activation and recruitment of various inﬂammatory cell
types including neutrophils, eosinophils, T cells and mast cells (Hirst,
2003). Furthermore, pro-inﬂammatory cytokines and chemokines from
ASM cells can induce AHR by enhancing ASM contraction and/or al-
tering ASM relaxation (Black, Panettieri, Banerjee, & Berger, 2012)
which may subsequently aﬀect airway structural cells responsible for
airway remodeling (Black et al., 2012; Koziol-White & Panettieri,
2011).
Another interesting feature of the ASM layer is that it has been
described as a niche for mast cells (Brightling et al., 2002; Slats et al.,
2007). It has been hypothesized that inﬁltration of these mast cells into
the ASM layer is of importance as mast-cell products can cause 1)
contraction and increase the responsiveness of ASM to bronchocon-
strictive stimuli, 2) ASM proliferation and ﬁbrosis and thereby con-
tribute to airway remodeling and bronchoconstriction, 3) ASM pro-in-
ﬂammatory cytokine release and surface protein expression (Page,
Ammit, Black, & Armour, 2001). Brightling et al. demonstrated a sig-
niﬁcant diﬀerence between the number of mast cells in the ASM in
patients with asthma and the number in both normal subjects and pa-
tients with eosinophilic bronchitis (Brightling et al., 2002). They also
observed an inverse relation between the number of mast cells in the
ASM of asthma patients and the provocative concentration of metha-
choline leading to a fall in forced expiratory volume in 1 s (FEV1) of
20% (PC20). In line with this observation, Slats et al. demonstrated an
association between mast cell counts in the ASM layer and an impaired
airway relaxation, thereby strengthening the potential contribution of
mast cell – ASM interaction to AHR in asthma (Slats et al., 2007).
Altogether, the altered ASM in asthma patients is versatile and in-
volved in multiple pathophysiological pathways of the asthmatic
airway ranging from airway inﬂammation to airway mechanics.
Although the true cause-eﬀect between ASM, airway pathophysiology
in asthma and functional/phenotypic features such as FEV1 and AHR
remains diﬃcult to determine, ASM can certainly be seen as a key
player.
2.2. Extra-cellular matrix (ECM) in asthma
Another component of airway remodeling is the ECM, which is in-
creasingly envisioned as an important contributor to pathophysiolo-
gical changes in airways diseases, including asthma. The ECM is a
complex network of proteins, glycoproteins and lipids, produced by
connective tissue cells including ASM, ﬁlling the extra-cellular space of
the (sub)mucosa (Bousquet et al., 1992). The ECM contributes to the
regulation of the airway and vascular diameter and prevent airways to
collapse during expiration (Vignola, Kips, & Bousquet, 2000). However,
next to this structural role, increased knowledge is gained about the
role of the ECM on ASM, inﬂammatory cells and angiogenesis (Vignola
et al., 2000). As such, in the airways of asthma patients, the proﬁle of
ECM proteins diﬀers from those in the non-asthmatic airway. In the
asthmatic airway it has been shown that there is enhanced deposition of
collagens I, III and V, ﬁbronectin, tenascin, hyaluronan, versican, la-
minin α2/β2 and perlecan whereas decorin, collagen IV and elastin are
decreased (Vignola et al., 2000). Also here, the ASM itself can con-
tribute to the ECM by producing growth factors and ECM components
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(Hirst, 2003; Vignola et al., 2000). Furthermore, the ECM deposited by
asthmatic ASM in vitro enhances the proliferative capacity of the ASM
cells (Johnson et al., 2004), which is in line with the observation that
ASM hyperplasia is associated with an increase in ECM in asthma
(James et al., 2012). Similarly, Arujo et al. reported increased fractions
of elastin and ﬁbronectin ﬁbers in the ASM of asthma patients (Araujo
et al., 2008). However, this is in contrast with observations of Yick et al.
who could not demonstrate diﬀerences in ECM gene expression in
biopsies of asthma patients and controls. Nevertheless, in asthma pa-
tients a relation between the fractional composition of the ECM in the
ASM layer and the dynamics of airway function was detected (Yick
et al., 2012), indicating that ECM components in the ASM layer con-
tributes to the physiological phenotype of asthma. In summary, the
ECM and ASM have important interactions which contribute to features
of airway remodeling and function.
2.3. Airway innervation in asthma
The nerves also play an important role in bronchoconstriction and
inﬂammation of the human airways (Groneberg, Quarcoo,
Frossard, & Fischer, 2004; Pisi, Olivieri, & Chetta, 2009; Scott & Fryer,
2012). The human airway innervation includes a cholinergic, adre-
nergic and non-adrenergic, non-cholinergic (NANC) innervation system
(Pisi et al., 2009). The cholinergic innervation consists of para-
sympathetic nerves that control primarily by signalling with acet-
ylcholine upon muscarinic receptors which can be found on most in-
ﬂammatory and airway structural cells including ASM and mucous
glands. This parasympathetic signalling mediates bronchoconstriction,
hypersecretion of mucus, inﬂammation and tissue remodeling
(Kistemaker, Oenema, Meurs, & Gosens, 2012; Scott & Fryer, 2012). As
such blocking the muscarinic receptors with inhaled anti-cholinergics,
such as tiotropium, has been demonstrated to be clinically eﬀective and
indeed has been approved for treatment of poorly controlled asthma
(Kerstjens et al., 2012). In COPD patients a new therapy ‘targeted lung
denervation’ (TLD) that is based on ablation of parasympathetic pul-
monary nerves surrounding the main bronchi is currently under in-
vestigation (Slebos et al., 2015). Theoretically this could be of beneﬁt
for asthma patients as well. The role of adrenergic innervation in reg-
ulating the bronchomotor tonus is less known. After increasing airway
resistance with propranolol in 21 asthma patients, blocking the alpha2-
adrenergic receptor with tolazoline (alpha-2-adrenergic receptor an-
tagonist) did not cause changes in the bronchomotor tonus in com-
parison to hexoprenaline (beta-2-adrenergic receptor agonist) and
ipratropium (anticholinergic) (Islami et al., 2014), suggesting that this
is not a primary mechanism in bronchomotor/bronchial tone (regula-
tion). By mechanical, thermal, chemical or inﬂammatory stimuli, the
NANC system releases neurotransmitters, including substance-P,
causing inﬂammation, mucus secretion, bronchoconstriction and vas-
cular activation resulting in microvascular leakage (Boot et al., 2007;
Groneberg et al., 2004). Indeed, inhaled substance P induces an in-
crease in the severity of maximal airway narrowing to methacholine
(Cheung, van der Veen, den Hartigh, Dijkman, & Sterk, 1994), which is
indicative of a role of the NANC system in AHR. Summarizing, the
diﬀerent airway innervation systems, most importantly the cholinergic
and NANC innervation systems, play a role in bronchomotor/bronchial
tone regulation and inﬂammation of the airways.
3. Bronchial Thermoplasty
Bronchial Thermoplasty (BT) is an endoscopic, minimally invasive
treatment for moderate-to-severe asthma based on local, radio-fre-
quency (RF) energy delivery to the larger airways, developed to prevent
excessive bronchoconstriction by reducing ASM (Cox, Miller,
Mitzner, & Leﬀ, 2004). As such BT is the ﬁrst asthma treatment that
targets airway remodeling instead of mainly modulating airway in-
ﬂammation and bronchomotor tone. The treatment consists of 3
bronchoscopies during which consecutively the right lower lobe, the
left lower lobe and the two upper lobes are treated. Through a standard
bronchoscope a basket catheter is brought to airways with a diameter of
~2 mm–10 mm where it delivers RF energy generated by the Alair
system (Boston Scientiﬁc, Natick, MA, USA) (Fig. 1). Each RF energy
delivery or activation takes 10 s and heats the airway to 65°. Diﬀerent
sedation strategies are described that vary from mild midazolam se-
dation to general anaesthesia. Recently, sedation anaesthesiology nurse
provided propofol-remifentanil sedation has been described that com-
bines high satisfaction and feasibility rates with a strong safety proﬁle
(d'Hooghe, Eberl, Annema, & Bonta, 2017).
Early animal studies showed a reduction in ASM mass at the area
where BT was applied that correlated to an improved AHR with di-
minished contraction in response to methacholine (Danek et al., 2004).
The ﬁrst application of BT in humans was performed in patients with
lung cancer who were scheduled to undergo lung resection. In this
study it was shown that BT of the human, non-asthmatic airways was
well tolerated and resulted in a signiﬁcant alteration of ASM, an ap-
proximate 50% reduction, in treated airway (Miller et al., 2005).
4. Clinical eﬃcacy of Bronchial Thermoplasty in asthma patients
The next step was to study BT in asthma patients. First, the safety
and impact on lung function and AHR of BT over 2 years in 16 mild-to-
moderate asthma patients was studied. Mild and moderate adverse
events were observed within 1 week after the procedure which resolved
spontaneously, with antibiotics or with a temporary increase of asthma
medication. There were no severe adverse events. Additionally, an
Fig. 1. Endoscopic view of asthmatic airways: left
image shows the opened basket catheter during a BT
activation resulting in RF energy delivery to a prox-
imal airway; right image shows blanching of the mu-
cosa of a proximal airway directly after BT.
Reprinted with permission of Ned Tijd
Allergy & Asthma 2017; 17: 26–32.
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improvement in AHR was found, that persisted until 2 years after BT
treatment (Cox, Miller, McWilliams, Fitzgerald, & Lam, 2006). Next, in
the AIR trial, an unblinded, randomized control trial (RCT), 112 mod-
erate-to-severe asthma patients who had been treated with ICS/LABA
where randomized to either BT treatment or a control group (Cox et al.,
2007). Patients treated with BT showed a reduced rate of mild ex-
acerbations as compared with baseline, which was unchanged in the
control group. Furthermore there was a signiﬁcant improvement in
asthma control (asthma control questionnaire, ACQ) and quality of life
(asthma quality of life questionnaire, AQLQ) in BT-treated patients as
compared to controls. There was no signiﬁcant diﬀerence in FEV1 and
the PC20 methacholine. During the treatment period there was an in-
crease in adverse respiratory events in patients treated with BT. Most
frequently observed adverse events where dyspnea, wheezing, cough
and chest discomfort. The majority of the adverse events occurred
within 1 day after the procedure and resolved an average within
1 week. Severe adverse respiratory events where asthma exacerbation
(n = 4), partial collapse of the left lower lobe (n = 1) and pleurisy
(n = 1) which resulted in hospitalization (Cox et al., 2007).
The RISA trial, a randomized unblinded trial, included 34 severe
asthma patients who had a signiﬁcant improvement versus control
subjects in quality of life (AQLQ), asthma control (ACQ) rescue medi-
cation use and pre-bronchodilator FEV1% predicted. These results
persisted when OCS and ICS were reduced, except for the pre-bronch-
odilator FEV1% predicted. As a result 4 of 8 BT treated patients, com-
pared to 1 of 7 control subjects were able to completely wean oﬀ OCS.
Also this study showed a short-term increase in asthma related mor-
bidity associated with BT (Pavord et al., 2007). In the largest, rando-
mized double blind, sham-controlled AIR-2 trial, 297 moderate-to-se-
vere asthma patients were randomized. 190 patients were randomized
to the BT group and 98 were randomized to the sham control group,
receiving 3 sham bronchoscopy procedures during which the BT
treatment was mimicked. The primary endpoint demonstrated a clini-
cally meaningful improvement in AQLQ score of 0.5 or greater in the BT
treated patients, which, to a lesser extend was also found in the sham-
controlled group, most probably due to placebo eﬀect. However, a
larger proportion of BT subjects compared with sham group subjects
experienced a clinically meaningful within-subject improvement in
AQLQ score of 0.5 or greater. Furthermore as secondary endpoints
fewer severe exacerbations, emergency department (ED) visits and days
missed from work were observed in the BT group. Likewise, an increase
in respiratory adverse events was seen in the treatment period in pa-
tients treated with BT (Castro et al., 2010). Unfortunately, to date these
studies were not able to deﬁne a speciﬁc asthma phenotype-based
responder proﬁle. Furthermore, it should be noted that patients who
have been included in the AIR and AIR2 trials where less severe than
the patients included in the RISA trial and recent non-randomized trials
(Castro et al., 2010; Chakir et al., 2015; Cox et al., 2007; Denner et al.,
2015; Pavord et al., 2007; Pretolani et al., 2017).
4.1. Long-term results of Bronchial Thermoplasty
The 3 randomized trials conducted follow-up trials to address the
eﬃcacy and safety up to 5 years after BT. In the AIR long-term study, 43
BT treated patients were followed for 5 years and 24 control patients
receiving standard of care where followed for 3 years. The rate of re-
spiratory adverse events, hospitalization and ED visits remained stable
over the 5 years following BT as compared to the year before BT.
Similar results were found for the control group up to 3 years.
Furthermore no deterioration in FEV1 or radiological abnormalities
where seen (Thomson et al., 2011).
The long-term results from the AIR-2 trial showed a sustained low
proportion of subjects experiencing severe exacerbations and ED visits
(average 5-year reduction in proportions: 44% for exacerbations and
78% for ED visits). Respiratory adverse events and hospitalizations
related to asthma remained unchanged. FEV1 remained stable and
structural airway abnormalities where excluded by a HRCT up to
5 years after BT treatment (Wechsler et al., 2013).
In accordance with the AIR and the AIR-2 long-term studies, the
follow-up study of the RISA trial patients demonstrated no deterioration
in respiratory adverse events, FEV1 or radiological abnormalities on
chest X-ray. Furthermore, a persistent decrease in hospitalizations and
ED visits was detected (Pavord et al., 2013). Unfortunately, the AIR-2
and the RISA trial did not have a control group to which the long-term
result were compared. Taken together, the long term follow-up results
of 3 randomized controlled trials are indicative that BT is safe, and
reduces asthma exacerbations, ED visits and hospitalization for at least
up to 5 years after BT treatment.
5. Emerging mechanisms underlying the clinical eﬀectiveness of
BT
Although demonstrated to be eﬀective on clinical outcomes in
randomized trials, the mechanism of the BT eﬀect is incompletely un-
derstood. Several mechanisms could potentially underlie the clinical
eﬀectiveness of BT (Wilhelm & Chipps, 2016). More likely, a combina-
tion of diﬀerent mechanisms will be responsible for the BT eﬀect as the
airways are a complex network of cells and structures with
Fig. 2. Schematic representation of airway pathophysiology in
asthma and the related potential mechanisms of action of
Bronchial Thermoplasty.
The diﬀerent components of airway wall pathophysiology in
asthma are illustrated. Airway smooth muscle (ASM) hyperplasia
and hypertrophy (bottom) with increased contractility and hy-
perresponsiveness. Increased amounts of pro-inﬂammatory cy-
tokines and chemokines produced by ASM can activate and re-
cruit inﬂammatory cells. Pro-inﬂammatory cytokines and
chemokines can contribute to airway hyperresponsiveness and
impact airway structural cells. Another feature observed is mast
cell inﬁltration in the ASM layer.
The ASM cells also produce extracellular matrix (ECM) growth
factors and ECM proteins, which can aﬀect the proliferative
capacity of the ASM cells.
At the top of the ﬁgure, the airway innervation (cholinergic,
adrenergic and non-adrenergic, non-cholinergic (NANC) sys-
tems) in asthma is illustrated. Nerves can contribute to bronch-
omotor/bronchial tone regulation and inﬂammation of the air-
ways.
The lightning bolts in the lumen of the airway represent the four
struts of the Bronchial Thermoplasty basket catheter that de-
livers RF energy to the airway wall with a potential eﬀect on the
above mentioned mechanisms.
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corresponding functions (Fig. 2).
5.1. Airway smooth muscle (ASM) reduction
Reducing the amount of airway smooth muscle, which is associated
with asthma severity, may result in an improvement of asthma symp-
toms and control. Preclinical studies have shown that BT reduces ASM
mass in canine model for asthma which was associated with a long term
reduction of AHR. The eﬀectiveness of BT on reducing the ASM mass in
asthma patients was ﬁrst demonstrated by Pretolani et al., analysing the
ASM mass percentage (%) (ASM area as % of the total biopsy area) in
airway biopsies 15 days before the ﬁrst BT and 3 months after treat-
ment with BT in 10 severe asthma patients. A reduction of ASM mass of
20.25% before BT to 7.28% (60%) after BT was found (Pretolani et al.,
2014). Next, Denner et al. observed an ASM reduction of 38% at the
ﬁrst BT to 16% (58%) 6 weeks after the ﬁrst BT (taken during the third
BT) in 11 patients (Denner et al., 2015). This was conﬁrmed with an
ASM reduction of 12.9% at the ﬁrst BT to 4.6% (64%) 3 weeks after the
ﬁrst BT (taken during the second BT) in another 17 patients (Chakir
et al., 2015).
Most recently, Pretolani et al. conﬁrmed reduction of ASM mass %
(ASM area as % of the submucosal tissue area) from 19.7% to 5.2%
(73%) in 15 severe asthma patients who were selected based on a
baseline ASM mass of 15% or more (Pretolani et al., 2017). Limitation
of the studies mentioned above is, that these were lacking an appro-
priate non-BT treated control group.
Despite this increasing evidence for the eﬃcacy of BT on reducing
the ASM, association with reductions in AHR are controversial. The
earlier detected improvement of AHR in canines and the ﬁrst 16 mild-
to-moderate asthma patients treated with BT could not be reproduced
in the AIR, RISA and AIR-2 trials (Castro et al., 2010; Cox et al., 2006,
2007; Pavord et al., 2007). Perhaps smaller dedicated studies with good
standardized PC20 measurements and well standardized BT adminis-
tration rather than large multicentre RCTs would be able to show an
association between ASM reduction and AHR. In addition, a large
variation of asthma phenotypes and potentially associated ASM phe-
notypes (e.g. contractile and synthetic, distribution of ASM through the
bronchial tree) included in the trials, could contribute to this lack of
association. Emphasizing that a decreased amount of ASM cells does not
automatically implies less contractility or decreased AHR, but that this
may depend on the ASM cells phenotype/distribution regardless of the
amount per se. Finally, PC20 methacholine/histamine as a measure that
is predominantly reﬂecting airway sensitivity to these agents may not
be the appropriate outcome to assess the eﬀects of BT on AHR. It is
likely that the degree of maximal airway narrowing to inhaled metha-
choline or other stimuli is a much better outcome of any changes in
ASM contractility (Sterk & Bel, 1989). However, changes in maximal
airway narrowing can only be quantiﬁed safely in patients with mild
asthma (Booms, Cheung, Timmers, Zwinderman, & Sterk, 1997).
Next to a reduction of ASM itself, any loss of contractile and re-
laxation function of ASM could play a role. In bovine ASM exposure to
extreme temperatures (> 55 °C) led to complete inhibition of the
contractile ASM function. This phenomenon occurred prior to necrosis
or apoptosis and appears to involve a disruption of the myosin. The
relaxation function was unchanged by thermal exposure (Dyrda et al.,
2011). It is beyond doubt that BT aﬀects the structure of airways and
the surrounding tissue after exposure to high temperature, as is con-
ﬁrmed by early radiological abnormalities reaching far peripheral to
the treated airway, seen on low dose CT's obtained 24 h after BT
(Debray et al., 2017; d'Hooghe, van den Berk, Annema, & Bonta, 2017).
Overall, a reduction in ASM following BT is plausible and demon-
strated in multiple studies. However, how the reduction of ASM relates
to the observed clinical eﬀects after BT is largely unknown. Whether
ASM mass can be used as a predictive marker in selecting patients that
beneﬁt from BT treatment needs to be determined.
5.2. Airway epithelium
The described extensive radiological abnormalities seen directly
after BT reinforce that BT certainly modiﬁes the airways (Debray et al.,
2017; d'Hooghe, van den Berk, et al., 2017). During BT, the airway
epithelium is the ﬁrst structure that the RF energy is delivered to which
can be noticed by blanching of the mucosa. The eﬀect of BT on the
epithelium was investigated by Pretolani et al. The amount of epithelial
neuroendocrine PGP-positive cells in the epithelial layer was dimin-
ished after BT (Pretolani et al., 2017). No impact of BT was found on the
proportion of regenerating epithelium or normal stratiﬁed columnar,
metaplastic, or squamous epithelium. More data are needed to look into
the modifying eﬀect of BT on the airway epithelium.
5.3. Inﬂammation
Since ASM produces pro-inﬂammatory cytokines and chemokines
itself, any BT induced reduction of ASM would imply a reduction of
those compounds in the airway wall. This potential eﬀect of BT on
airway inﬂammation is another mechanism that could contribute to the
beneﬁts of BT. One study investigated cytokines associated with asthma
airway inﬂammation in bronchoalveolar lavage (BAL) 3 and 6 weeks
after BT treatment and found a signiﬁcant reduction of TGF-β and
RANTES whereas other asthma key cytokines including eotaxin, IL-4,
IL-5, IL-6, IL-13 en IL-17 were unchanged (Denner et al., 2015). Also the
percentage of eosinophils appeared to be signiﬁcantly reduced. The
possible inﬂuence of the (understandable) prophylactic high dose of
prednisolone given shortly before the sampling is however a potential
bias of this study (Denner et al., 2015). In airway biopsies taken
3 months after BT, Pretolani et al. found no eﬀect of BT on mucosal
eosinophils and neutrophils (Pretolani et al., 2017).
Furthermore, the observed increase of mast cells within the ASM
layer in asthma and its relationship with increased AHR (Brightling
et al., 2002) and impaired airway relaxation (Slats et al., 2007) implies
that reducing the mast cells by ablation of ASM niche of these cells
could play a role in the mechanism of action of BT. To the best of our
knowledge there are no data on mast cell numbers within ASM before
and after BT. Considering the pivotal role of the mast cell in atopic
asthma, one might hypothesize that atopic asthma patients could be
high responders for BT. In the currently ongoing TASMA study (Clin.
Trials.gov nr: NCT02225392) the eﬀect of BT on ASM and related
airway inﬂammation will be further investigated.
Is there any eﬀect of BT on systemic inﬂammation? A retrospective
review in 10 BT treated severe asthma patients showed a signiﬁcant
reduction in blood eosinophil count 1 year after BT treatment (Ryan,
Fowler, & Niven, 2016). The question whether a BT-induced eﬀect can
be expected on airway inﬂammation and which inﬂammatory cells are
modulated largely remains unanswered.
5.4. ECM
Is there any role for ECM in the eﬀects of BT in asthma? In 17 severe
asthma patients a decreased type 1 collagen deposition was described
shortly after the ﬁrst BT when examined at subsequent BT treatments
(Chakir et al., 2015). This eﬀect remained unchanged after 27 months
in 9 of these BT treated patients who consented for another broncho-
scopy (Salem et al., 2016). A decrease in thickness of the subepithelial
reticular basement membrane (RBM) was conﬁrmed by Pretonali et al.,
however these authors also observed a signiﬁcantly larger proportion of
the biopsy area stained for collagen (Pretolani et al., 2017). Considering
these partly opposing results regarding the eﬀect of BT on ECM larger
sample sizes with non-BT treated controls are needed. Furthermore, the
mechanism how BT impacts on ECM is unknown. It could be postulated
that BT directly eﬀects the ECM composition or that BT indirectly af-
fects ECM composition by reducing the ECM-protein-producing ASM
and other structural cells. Considering the important interaction
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between the ECM and ASM described above, BT induced changes in the
ECM may contribute to the eﬃcacy of BT.
5.5. Neural innervation and vascular function
What is the evidence of BT impact on neural or vascular structure?
Impact of BT on the neural innervation was found in airway biopsies
3 months after BT by a single study by Pretolani et al. Both submucosal
and ASM associated nerve ﬁbers were signiﬁcantly reduced and a 95%
reduction of neuroendocrine epithelial cells was detected. Interestingly,
also the non-BT treated right middle lobe (RML) showed a down-
regulation of these neuroendocrine epithelial cells. No signiﬁcant eﬀect
was seen on the density of submucosal blood vessels (Pretolani et al.,
2017). More studies are needed to elucidate the BT induced eﬀects on
neural innervation and vascularisation. It might even be postulated that
any BT eﬀects on neural innervation or vascularisation is spreading out
to distal untreated airway areas, even though BT is delivered to the
larger airways (airway diameter ~2 mm and larger). Considering the
anatomy of the neural innervation and vascularisation system running
along the entire bronchial tree from proximal to the smallest distal
airways, it is imaginable that a BT-induced proximal interruption in the
larger airways impacts the smaller distal airways.
6. Future perspectives
The available data on the potential mechanisms underlying the
clinical eﬀectiveness of BT makes it unlikely that only one feature of
airway pathophysiology in severe asthma is modulated by BT for the
observed clinical beneﬁts. The eﬀectiveness of BT is more likely a
consequence of its impact on a complex interplay between various
airway pathophysiological components of which airway remodeling
including ASM is a key player. Results are awaited from large registries
and (randomized) trials, such as the TASMA trial (Clin.Trials.gov nr:
NCT02225392), investigating the mechanism of action of BT and trying
to deﬁne clinical parameters and biomarkers that diﬀerentiate the re-
sponders from the non-responders of this therapy. The latter would be
very valuable for selecting patients to receive this novel treatment
modality in this heterogeneous disease. Extended severe asthma phe-
notyping might therefore contribute to further personalized asthma
treatment by BT. Next to phenotyping by clinical, molecular, patho-
physiological and functional parameters as described above, also novel
high resolution imaging techniques, such as optical coherence tomo-
graphy (OCT) (Huang et al., 1991) might contribute to this. Indeed OCT
has been shown eﬀective in in-vivo quantiﬁcation of airway wall di-
mensions, remodeling and even ASM content (Adams et al., 2016; Chen
et al., 2015; Coxson & Lam, 2009; Coxson et al., 2008; Ding et al.,
2016). Therefore, OCT can potentially contribute to severe asthma
phenotyping with a focus on airway remodeling and ASM mass and
serve as a possible instrument for patient selection for BT and/or
monitoring treatment response after BT (Kirby et al., 2015). In addition
there could even be a role of BT-induced changes in bronchial micro-
biome as potential modulator of the clinical control of asthma (Sullivan,
Hunt, MacSharry, &Murphy, 2016).
7. Conclusions
Bronchial Thermoplasty is an endoscopic treatment for moderate-to-
severe asthma patients who are uncontrolled despite optimal medical
treatment. By local RF energy delivery to the airways BT aims to reduce
the ASM mass, one of the key features of airway remodeling. However,
the mechanism of action of BT is likely to be more complex than solely
the ASM reduction and is still incompletely understood. More results
are needed to elucidate the eﬀect of BT on airway pathophysiology
including airway remodeling and innervation, which will contribute to
deﬁne the severe asthma phenotype that beneﬁts most of this novel
treatment modality..
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